Search for Clinical Trial Results

Sponsored By

Primary Agammaglobulinemia - 13 Studies Found

Status Study
Completed Study Name: A Study of the Safety and Efficacy of Vigam® Liquid in Patients With Primary or Secondary Antibody Deficiency
Condition: Primary or Secondary Antibody Deficiency (PAD or SAD).
Date: 2014-09-02
Interventions: Biological: Vigam® (Human Normal Immunoglobulin)
Recruiting Study Name: Assessment of Immunogenicity of Zostavax® in Patients With Antibody Deficiency 60 Years of Age and Older
Condition:
  • Common Variable Immune Deficiency
  • Specific Antibody Deficiency<
    Date: 2016-10-03
    Interventions: Biological: Zostavax® Zostavax® immunization
Recruiting Study Name: Polysaccharide Antibody Response Study
Condition: Specific Polysaccharide Antibody Deficiency
Date: 2015-02-19
Interventions:
  • Biological: Pneumovax 23 (Sanofi Pasteur MSD)

Completed Study Name: Specific IgG Antibody in Patients With Primary Antibody Deficiencies Treated With Subcutaneous Immunoglobulin
Condition:
  • Common Variable Immunodeficiency
  • Agammaglobulinemia

Date: 2008-04-14
Interventions: Biological: gammaglobulin They were administered a polyvalent, pasteurized liquid immune globulin subcut
Completed Study Name: A Multi-centre Open Study to Assess the Safety and Efficacy of Subgam®
Condition: Primary Antibody Deficiency.
Date: 2014-09-02
Interventions: Biological: Subgam® (Human Normal Immunoglobulin Solution)
Completed Study Name: Construction of a Health-related Quality of Life (HR-QOL) Questionnaire for Patients With Primary Antibody Deficiency Disease
Condition: Immune Deficiency, Antibody
Date: 2015-08-31
Interventions: Other: questionnaire survey The HR-QOL PIDD survey will be administered to the patient by the site PI or
Completed Study Name: Efficacy and Safety Study of Kedrion IVIG 10% to Treat Subjects With Primary Immunodeficiency (PID)
Condition:
  • Primary Immunodeficiency
  • Agammaglobulinemia
  • Hypogammaglobu
    Date: 2012-04-16
    Interventions: Biological: Kedrion IVIG 10% Dosage form - Intravenous (IV) infusion of Kedrion IVIG 10%; Dosage - 300 t
Completed Study Name: Pharmacokinetics, Efficacy, and Safety Study of RI-002 (IGIV) in Subjects With Primary Immunodeficiency Diseases (PIDD)
Condition: Primary Immune Deficiency Disorder
Date: 2013-03-06
Interventions: Biological: RI-002 Immune Globulin Intravenous (IGIV)
Recruiting Study Name: Systematic Search for Primary Immunodeficiency in Adults With Infections
Condition: